Luk Vandenberghe, PhD

Luk Vandenberghe, PhD, Builds Designer Viruses for Improved Gene Therapy

December 19, 2018

Luk Vandenberghe, PhD

In Nature, Luk Vandenberghe, PhD, Harvard Medical School Associate Professor of Ophthalmology and Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear, discusses increasing the efficiency of gene therapies by manipulating the viral vectors that transport genes into cells. He also talks about taking a nonprofit approach to tackle the economics of developing gene therapy for rare diseases.... Read more about Luk Vandenberghe, PhD, Builds Designer Viruses for Improved Gene Therapy

Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness

March 7, 2018

New nonprofit organization will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases.

Luk Vandenberghe in laboratory

Boston, Mass. — Scientists and advocates today announced the formation of ...

Read more about Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness
Luk Vandenberghe

Luk H. Vandenberghe, PhD, to receive Foundation Fighting Blindness Award

August 15, 2017

Luk H. Vandenberghe, PhD, along with collaborator and lead author Rob Collin, PhD, of Radboud University Medical Center, has been selected to receive the 2017 Ed Gollob Board of Directors’ Award from the Foundation Fighting Blindness (FFB). This award is presented annually in recognition of significant research advancements. According to the FFB, their winning paper, “In vitro and in vivo rescue of aberrant splicing in CEP290-...

Read more about Luk H. Vandenberghe, PhD, to receive Foundation Fighting Blindness Award
Luk Vandenberghe

Luk H. Vandenberghe, PhD, receives RPB Nelson Trust Award for Retinitis Pigmentosa

December 21, 2016

Boston, Mass. — Luk H. Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear and an Assistant Professor of Ophthalmology at Harvard Medical School, has been awarded a Nelson Trust Award for Retinitis Pigmentosa by Research to Prevent Blindness (RPB) in the amount of $100,000 over two years. The Nelson Trust Award was established to stimulate, strengthen and accelerate research to improve...

Read more about Luk H. Vandenberghe, PhD, receives RPB Nelson Trust Award for Retinitis Pigmentosa
Luk Vandenberghe

Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear

September 12, 2016
  • The strategic licensing agreement between Lonza and Massachusetts Eye and Ear® underscores Lonza’s position as a leading AAV manufacturing service provider and offers customers unprecedented technology and services to commercialize next generation gene therapies.
  • The Anc-AAV vector platform has the potential to overcome pre-existing immunity in order to treat more patients compared with other viral vectors currently in development.
  • Anc80, the lead novel Anc-AAV available for sublicensing, is a potent gene therapy vector capable of superior gene expression levels in...
Read more about Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with Massachusetts Eye and Ear
Luk Vandenberghe

Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear

May 19, 2016

Selecta is licensing Anc80 from Massachusetts Eye and Ear for a rare genetic disease with options on additional pre-specified indications. By combining Anc80 with Selecta’s investigational drug candidate, SVP-Rapamycin (SEL-110), Selecta is seeking to advance a new gene therapy platform designed to avoid several immunogenicity challenges that limit the development of gene therapies today 

Watertown, Mass. — Selecta Biosciences, Inc., a clinical-stage biopharmaceutical...

Read more about Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear

Honors and Awards Received January-February 2016

February 15, 2016

Dong Feng Chen, PhD,  received a National Institutes of Health/National Eye Institute R01 grant in the amount of $2,462,500 over five years for her project, "The molecular basis underlying optic nerve growth in development and regeneration."

Miguel Gonzalez, MD, PhD, a Cornea KPro Research Fellow at Mass. Eye and Ear, received membership to the Royal Academy of Medicine and...

Read more about Honors and Awards Received January-February 2016
Researchers Resurrect Ancient Viruses in Hopes of Improving Gene Therapy

Researchers Resurrect Ancient Viruses in Hopes of Improving Gene Therapy

July 30, 2015

Boston, MA Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina. This discovery, published July 30 in Cell Reports, could potentially be used to design gene therapies that are not only safer and more potent than therapies currently...

Read more about Researchers Resurrect Ancient Viruses in Hopes of Improving Gene Therapy